Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
HC Wainwright & Co. Maintains Buy on Minerva Neurosciences, Lowers Price Target to $10
10:37am, Monday, 08'th Jun 2020ACADIA Pharmaceuticals: The Worst-Case Scenario For Investors (NASDAQ:ACAD)
12:01am, Monday, 08'th Jun 2020
Under every scenario below, it is possible for investors to see a positive investment return. It is necessary to follow which variant the company is taking, as
Hearing JMP Securities is Reinstating its Market Outperform Rating on Minerva Neurosciences with a $9 Price Target
05:34pm, Friday, 05'th Jun 2020Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session
01:05pm, Friday, 05'th Jun 2020
Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Coronavirus Roundtable - Still Some Dancing To Be Done
10:30am, Friday, 05'th Jun 2020
We ask trading-oriented authors on the Marketplace to share their view on the eventful 2020 market. There's something of a consensus that the market is overboug
Meat giants selling to UK linked to Brazil farms in deforested Amazon reserve
08:00am, Friday, 05'th Jun 2020
Greenpeace report shows cattle indirectly sold to JBS, Marfrig and Minerva came from protected Serro Ricardo Franco park
Revealed: UK banks and investors' $2bn backing of meat firms linked to Amazon deforestation
08:00am, Thursday, 04'th Jun 2020
Investigation uncovers ties between financial institutions and three Brazilian firms connected to environmental destruction
How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry
01:00pm, Tuesday, 02'nd Jun 2020
Minerva Neurosciences (NERV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Minerva Neurosciences Is Heading Higher Today
06:15pm, Monday, 01'st Jun 2020
Minerva Neurosciences (NASDAQ: NERV), a small-cap biotech, is rebounding a bit Monday after a dramatic plunge on Friday. The drug did no better than a placebo on either the study's primary endpoint
Mid-Morning Market Update: Markets Edge Higher; Zynga To Buy Mobile Game Developer Peak For $1.8B
02:18pm, Monday, 01'st Jun 2020
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the company will
